250 related articles for article (PubMed ID: 17532101)
1. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
Kshirsagar N; Mur N; Thatte U; Gogtay N; Viviani S; Préziosi MP; Elie C; Findlow H; Carlone G; Borrow R; Parulekar V; Plikaytis B; Kulkarni P; Imbault N; LaForce FM
Vaccine; 2007 Sep; 25 Suppl 1():A101-7. PubMed ID: 17532101
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
3. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.
Lee CH; Kuo WC; Beri S; Kapre S; Joshi JS; Bouveret N; LaForce FM; Frasch CE
Vaccine; 2009 Jan; 27(5):726-32. PubMed ID: 19063929
[TBL] [Abstract][Full Text] [Related]
8. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
[TBL] [Abstract][Full Text] [Related]
10. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Sow SO; Okoko BJ; Diallo A; Viviani S; Borrow R; Carlone G; Tapia M; Akinsola AK; Arduin P; Findlow H; Elie C; Haidara FC; Adegbola RA; Diop D; Parulekar V; Chaumont J; Martellet L; Diallo F; Idoko OT; Tang Y; Plikaytis BD; Kulkarni PS; Marchetti E; LaForce FM; Preziosi MP
N Engl J Med; 2011 Jun; 364(24):2293-304. PubMed ID: 21675889
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier.
Pérez AE; Dickinson FO; Banderas F; Serrano T; Llanes R; Guzmán D; Díaz P; Alvarez A; Guirola M; Caballero E; Canaan-Haden L; Guillén G
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):386-92. PubMed ID: 16553812
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
14. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.
Campbell JD; Edelman R; King JC; Papa T; Ryall R; Rennels MB
J Infect Dis; 2002 Dec; 186(12):1848-51. PubMed ID: 12447774
[TBL] [Abstract][Full Text] [Related]
15. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
16. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
[TBL] [Abstract][Full Text] [Related]
17. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
Knuf M; Kieninger-Baum D; Habermehl P; Muttonen P; Maurer H; Vink P; Poolman J; Boutriau D
Vaccine; 2010 Jan; 28(3):744-53. PubMed ID: 19887137
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.
Granoff DM; Morgan A; Welsch JA
Vaccine; 2005 Jul; 23(34):4307-14. PubMed ID: 15921829
[TBL] [Abstract][Full Text] [Related]
19. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
